Cellectis(OTC) CMVLF

Current Price$3.47

Market Cap$250.97M

Since IPO (2013)-25%

5 Year-77%

1 Year+178%

1 Month+13%

Cellectis last closing stock price
Metric	Price	Date
Last close	USD 3.47	2026-06-03

Cellectis stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+12.66%	USD 3.08	2026-04-02
1 month	+12.66%	USD 3.08	2026-04-02
3 month	-21.14%	USD 4.40	2026-01-05
Year to date	-21.14%	USD 4.40	2025-12-30
1 year	+177.6%	USD 1.25	2025-06-02
3 year	+82.63%	USD 1.90	2023-06-01
5 year	-76.8%	USD 14.96	2021-06-04
Since inception	-25.18%	USD 4.64	2013-10-31

Cellectis Financials at a Glance

Market Cap

$250.97M

Revenue (TTM)

$68.09M

Net Income (TTM)

-$67.25M

EPS (TTM)

-$0.67

P/E Ratio

-5.18

Dividend

$0.00

Beta (Volatility)

0.09 (Low)

Dividend

$0.00

Beta (Volatility)

0.09 (Low)

Price

$3.47

Volume

Open

$3.47

Price

$3.47

Volume

Open

$3.47

Previous Close

$3.47

Daily Range

$3.47 - $3.47

52-Week Range

$2.58 - $5.04

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

0.09 (Low)

Price

$3.47

Volume

Open

$3.47

Previous Close

$3.47

Daily Range

$3.47 - $3.47

52-Week Range

$2.58 - $5.04

Estimated Earnings Date

Aug 11, 2026

CMVLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cellectis

Cellectis S.A. is a clinical-stage biotechnology firm focused on developing innovative immuno-oncology therapies. The company specializes in engineering T-cells using gene editing to create chimeric antigen receptors (CARs) that target and eliminate cancer cells.

Products and Services

UCART19: Allogeneic T-cell therapy for CD19-expressing blood cancers
ALLO-501 and ALLO-501A: Treatments for relapsed/refractory diffuse large B-cell lymphoma
ALLO-316: Targeting renal cell carcinoma and other promising candidates

Growth Outlook

Strong pipeline with multiple candidates in clinical trials
Strategic partnerships enhancing research and development capabilities
Focus on expanding therapeutic applications in oncology

Financial Highlights

Recent quarterly revenue of $5.7 million, showing potential growth
Trailing twelve months (TTM) revenue of $35.2 million, indicating market interest
Cash and short-term investments totaling $186.2 million, providing operational flexibility

Cellectis S.A. operates in the dynamic biotechnology sector, with a focus on immuno-oncology therapies that leverage cutting-edge gene editing technologies. The company's product pipeline includes several promising candidates, particularly in the treatment of various blood cancers. Recent financial performance indicates a revenue of $5.7 million for the latest quarter, contributing to a TTM revenue of $35.2 million, which reflects growing market interest in its innovative therapies. Additionally, the company maintains a robust cash position with $186.2 million in cash and short-term investments, allowing for continued investment in research and development. Strategic partnerships further enhance Cellectis's capabilities, positioning the company for future growth in the competitive biotechnology landscape.

AI Generated • Jul 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

229

CEO

André Choulika, PhD

Website

www.cellectis.com

Headquarters

Paris, 75013, FR

CMVLF Financials

Key Financial Metrics (TTM)

Gross Margin

78.86%

Operating Margin

-69.23%

Net Income Margin

-98.69%

Return on Equity

-80.61%

Return on Capital

-21.45%

Return on Assets

-23.26%

Earnings Yield

-19.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$250.97M

Shares Outstanding

72.33M

Volume

Avg. Volume

22.645

Financials (TTM)

Gross Profit

$47.63M

Operating Income

-$54.49M

EBITDA

-$45.01M

Operating Cash Flow

-$37.77M

Capital Expenditure

-$2.23M

Free Cash Flow

-$40.00M

Cash & ST Invst.

$186.17M

Total Debt

$108.90M

Cellectis Performance Analysis

Cellectis annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 19,171,000	-36.8%
2023	2023-12-31	USD 755,000	-96.1%
2024	2024-12-31	USD 41,505,000	5397.4%
2025	2025-12-31	USD 72,949,000	75.8%

Cellectis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	57.0%
Q3	2025-09-30	110.3%
Q4	2025-12-31	-70.2%
Q1	2026-03-31	-45.6%

Cellectis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.33	-8.5%
2023	2023-12-31	USD -1.77	-23.9%
2024	2024-12-31	USD -0.41	-77.1%
2025	2025-12-31	USD -0.67	66.1%

Cellectis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-38.9%
Q3	2025-09-30	102.4%
Q4	2025-12-31	-4506.8%
Q1	2026-03-31	34.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$5.71M

-46.5%

Gross Profit

$1.23M

-85.8%

Gross Margin

21.50%

N/A

Market Cap

$250.97M

N/A

Market Cap/Employee

$1.16M

N/A

Employees

216

N/A

Net Income

-$17.54M

+3.2%

EBITDA

-$22.19M

-96.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$186.17M

-23.0%

Total Debt

$108.90M

+18.7%

Accounts Receivable

$15.09M

-40.9%

Inventory

$0.00

N/A

Long Term Debt

$93.70M

+18.8%

Short Term Debt

$15.20M

+17.8%

Return on Assets

-23.26%

N/A

Return on Invested Capital

-30.50%

N/A

Free Cash Flow

-$15.57M

+11.3%

Operating Cash Flow

-$15.31M

+10.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CYDYCytoDyn Inc.

CYDYCytoDyn Inc.$0.20-6.54%

NWBONorthwest Biotherapeutics, Inc.

NWBONorthwest Biotherapeutics, Inc.$0.17+0.53%

SLNCFSilence Therapeutics plc

SLNCFSilence Therapeutics plc$1.50+0.00%

CLVLFClinuvel Pharmaceuticals Limited

CLVLFClinuvel Pharmaceuticals Limited$6.10+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

NUNu Holdings

NUNu Holdings$14.09-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

Questions About CMVLF

What is the current price of Cellectis?

Cellectis is trading at $3.47 per share.

What is the 52-week range for Cellectis?

Over the past 52 weeks, Cellectis has traded between $2.58 and $5.04.

How much debt does Cellectis have?

As of the most recent reporting period, Cellectis reported total debt of $108.60M.

How much cash does Cellectis have on hand?

Cellectis reported $35.00M in cash and cash equivalents in its most recent financial results.

What is Cellectis’s dividend yield?

Cellectis does not currently have a dividend yield.

Cellectis(OTC) CMVLF

Cellectis Financials at a Glance

CMVLF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cellectis

CMVLF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cellectis Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CMVLF

What is the current price of Cellectis?

What is the 52-week range for Cellectis?

How much debt does Cellectis have?

How much cash does Cellectis have on hand?

What is Cellectis’s dividend yield?

Premium Investing Services